Change in treatment regime for cryptococcal meningitis may be needed

September 25, 2012

The most cost-effective treatment for cryptococcal meningitis (a serious infection of the brain membranes, usually in people with AIDS or other immune system deficiencies) is different to that currently recommended by the World Health Organization (WHO), warranting a review of policy, according to the findings of a study published in this week's PLOS Medicine.

Researchers from Makerere University in Kampala, Uganda, and from the University of Minnesota in the US found that a short (7-day) course of amphotericin along with high-dose fluconazole for at least 2 weeks is the most cost-effective and least toxic treatment for cryptococcal meningitis.

The authors reached their conclusions by calculating the overall cost of six induction treatments for cryptococcal meningitis in HIV-infected patients using 2012 in Uganda for drugs, supplies, and hospital care, and average laboratory costs for monitoring treatment from three . Then they estimated the survival, cost, and cost per benefit associated with each treatment.

Currently, WHO recommends a 14-day regimen of injected amphotericin (a very toxic drug) and oral flucytosine or fluconazole for induction therapy of cryptococcal meningitis, but this regimen is impractical in many because of the cost of the drugs and ; so high-dose fluconazole alone is the usual treatment, even though this regimen is much less effective resulting in more deaths.

The authors say: "Short-course (7-day) amphotericin induction therapy coupled with high-dose fluconazole is very cost effective per criteria and may be a worthy investment for policy-makers seeking cost effective ."

They add: "Amphotericin should be moved from the ''complementary list'' to the ''core list'' in the WHO Model List of Essential Medications."

In an accompanying Perspective article, Andrew Farlow from the University of Oxford (uninvolved in the study) says that two results stand out: "First, the least cost-effective regimen is high-dose fluconazole monotherapy, which has been associated with a nearly 2-fold higher 10- week mortality rate and about 30% greater absolute mortality than the short course (5-7 days) amphotericin-based regimen. Second, long-course (14 days) amphotericin-based regimens, as recommended by the World Health Organization are not only more costly but appear to be no more effective than short course amphotericin-based regimens."

Farlow adds: "If the second finding is confirmed in further trials, the World Health Organization will need to adjust its advice."

Explore further: XPert MTB/RIF cost effective for TB diagnosis in low- and middle-income settings

More information: Rajasingham R, Rolfes MA, Birkenkamp KE, Meya DB, Boulware DR (2012) Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Med 9(9): e1001316. doi:10.1371/journal.pmed.1001316

Related Stories

XPert MTB/RIF cost effective for TB diagnosis in low- and middle-income settings

November 8, 2011
A study led by Frank Cobelens of the Amsterdam Institute of Global Health and Development, Amsterdam, The Netherlands and colleagues reports on the cost-effectiveness of implementing the Xpert MTB/RIF diagnostic test for ...

Shorter malaria treatment proven as effective in treating seriously ill children as standard course

December 19, 2011
(Medical Xpress) -- A shorter anti-malaria treatment is as effective in treating seriously ill children as the standard regimen, according to new research. Researchers have shown that three doses over two days of the drug ...

Biologists prove ZOLOFT packs potential to fight fungal meningitis

July 25, 2012
New research conducted by biologists at Texas A&M University suggests that ZOLOFT, one of the most widely prescribed antidepressants in the world, also packs a potential preventative bonus — potent mechanisms capable ...

Recommended for you

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.